CYP2D6 genotype and optimization of breast cancer treatment

被引：0
|
作者：
Bandres, F. [1 ]
Chicharro, L. M. [2 ]
Tejerina, A. [1 ]
del Saz, M. [2 ]
Fernaacutendez-Santander, A. [2 ]
机构：
[1] Fdn Tejerina, Unidad Docente, Madrid, Spain
[2] Univ Europea Madrid, Madrid, Spain
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 03期
关键词：
D O I：
10.1016/S1359-6349(10)70446-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：179 / 179
页数：1
相关论文
共 50 条
  • [1] Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism:: Implication for optimization of breast cancer treatment
    Borges, Silvana
    Desta, Zeruesenay
    Li, Lang
    Skaar, Todd C.
    Ward, Bryan A.
    Nguyen, Anne
    Jin, Yan
    Storniolo, Anna Maria
    Nikoloff, D. Michele
    Wu, Lin
    Hillman, Grant
    Hayes, Daniel F.
    Stearns, Vered
    Flockhart, David A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (01) : 61 - 74
  • [2] CYP2D6 GENOTYPE FREQUENCIES IN BREAST-CANCER PATIENTS
    BUCHERT, E
    WOOSLEY, RL
    OLIVER, S
    SWAIN, S
    RIEGEL, AT
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 53 (02) : 214 - 214
  • [3] Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes
    Madlensky, L.
    Natarajan, L.
    Tchu, S.
    Pu, M.
    Mortimer, J.
    Flatt, S. W.
    Nikoloff, D. M.
    Hillman, G.
    Fontecha, M. R.
    Lawrence, H. J.
    Parker, B. A.
    Wu, A. H. B.
    Pierce, J. P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (05) : 718 - 725
  • [4] Is CYP2D6 phenotype predictable from CYP2D6 genotype?
    Kiss, Adam Ferenc
    Toth, Katalin
    Juhasz, Cintia
    Temesvari, Manna
    Paulik, Jozsef
    Hirka, Gabor
    Monostory, Katalin
    MICROCHEMICAL JOURNAL, 2018, 136 : 209 - 214
  • [5] CYP2D6 genotype and treatment with tricyclic antidepressants
    Tandon, K
    Schalkwyk, L
    Checkley, S
    Patel, M
    Kinirons, M
    Kerwin, RW
    McGuffin, P
    Aitchison, KJ
    AMERICAN JOURNAL OF MEDICAL GENETICS, 2002, 114 (07): : 775 - 775
  • [6] CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment
    Jin, Y
    Desta, Z
    Stearns, V
    Ward, B
    Ho, H
    Lee, KH
    Skaar, T
    Storniolo, AM
    Li, L
    Araba, A
    Blanchard, R
    Nguyen, A
    Ullmer, L
    Hayden, J
    Lemler, S
    Weinshilboum, RM
    Rae, JM
    Hayes, DF
    Flockhart, DA
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (01): : 30 - 39
  • [7] Impact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment
    Stingl, Julia Carolin
    Parmar, Sumit
    Huber-Wechselberger, Ariana
    Kainz, Alexander
    Renner, Wilfried
    Seeringer, Angela
    Brockmoeller, Juergen
    Langsenlehner, Uwe
    Krippl, Peter
    Haschke-Becher, Elisabeth
    CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (11) : 2535 - 2542
  • [8] FORTY NINE BREAST CANCER PATIENTS WITH THE CYP2D6*4/*4 GENOTYPE
    Dieudonne, A.
    Neven, P.
    Wildiers, H.
    Christiaens, M.
    Weltens, C.
    Vergote, I.
    Lambrechts, D.
    ANNALS OF ONCOLOGY, 2009, 20 : 53 - 53
  • [9] CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer
    He, Wei
    Grassmann, Felix
    Eriksson, Mikael
    Eliasson, Erik
    Margolin, Sara
    Thoren, Linda
    Hall, Per
    Czene, Kamila
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06) : 548 - +
  • [10] RELATIONSHIP OF CYP2D6 (DEBRISOQUINE HYDROXYLASE) GENOTYPE TO BREAST-CANCER SUSCEPTIBILITY
    BUCHERT, ET
    WOOSLEY, RL
    SWAIN, SM
    OLIVER, SJ
    COUGHLIN, SS
    PICKLE, L
    TROCK, B
    RIEGEL, AT
    PHARMACOGENETICS, 1993, 3 (06): : 322 - 327
12345